A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.

@article{Bedikian2008APS,
  title={A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.},
  author={Agop Y. Bedikian and Nicholas E J Papadopoulos and Kevin B Kim and Anna G Vardeleon and Teresa Rust Smith and Biao Lu and Steven R. Deitcher},
  journal={Melanoma research},
  year={2008},
  volume={18 6},
  pages={400-4}
}
Vincristine sulfate liposome infusion (VSLI) is a sphingomyelin/cholesterol liposome encapsulated formulation of vincristine that results in an extended drug circulation time and the potential for enhanced malignancy targeting, exposure, and anticancer activity. We assessed the safety and activity of VSLI in patients with metastatic melanoma. VSLI, to provide VCR 2.0 mg/m without dose capping, was infused over 1 h every 2 weeks (one cycle). Safety, tumor response, and survival were determined… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…